Esophageal mast cells may be associated with the perception of symptoms in patients with eosinophilic esophagitis

Kanamori, Atsushi; Tanaka, Fumio; Takashima, Shingo; Ominami, Masaki; Nadatani, Yuji; Fukunaga, Shusei; Otani, Koji; Hosomi, Shuhei; Kamata, Noriko; Nagami, Yasuaki; Taira, Koichi; Watanabe, Toshio; Fujiwara, Yasuhiro

doi:10.1007/s10388-022-00967-w

Cited by 9 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 22 Moreover, in patients with EoE, mast cells may be associated with symptom perception. 24 Taken together, in patients with non‐EoE EGIDs, mast cells may be involved in the sequence of not only Th2‐mediated immune response but also neuroimmune response.…”

Section: Discussionmentioning

confidence: 99%

Correlation between anxiety and decreased quality of life in patients with non‐esophageal eosinophilic gastrointestinal diseases

Tanaka,

Kanamori,

Sawada

et al. 2023

JGH Open

Self Cite

View full text Add to dashboard Cite

Background and AimMental status such as anxiety and depression in patients with non‐esophageal eosinophilic gastrointestinal diseases (non‐EoE EGIDs) has not been studied. The aim of this study was to evaluate whether patients with non‐EoE EGIDs had mental disorders and decreased mental‐health‐related quality of life (QOL) similar to those in patients with disorders of gut–brain interaction (DGBI).MethodsWe enrolled patients with non‐EoE EGIDs and DGBI visiting the Osaka Metropolitan University Hospital, and the measures listed below were compared between the groups. We collected data using the following questionnaires: hospital anxiety and depression scale, and short form (SF)‐8 including mental component summary (MCS)‐8.ResultsWe evaluated 21 and 17 patients with non‐EoE EGIDs and DGBI, respectively. The anxiety score was not significantly different between the groups. The proportion of patients with possible anxiety was not significantly different between the groups (19.0% vs 33.3%). These results show that patients with non‐EoE EGIDs had anxiety that might be equivalent to that of patients with DGBI. The depression score and proportion of patients with possible depression in the non‐EoE EGID group tended to be lower than those in the DGBI group. MCS‐8 scores were not significantly different between the non‐EoE EGID and DGBI groups, which might imply an equivalent decrease in mental‐health‐related QOL in both groups of patients. In patients with non‐EoE EGIDs, the anxiety score had a significant inverse association with the MCS‐8 score.ConclusionsPatients with non‐EoE EGIDs may have anxiety that correlates with decreased mental‐health‐related QOL.

show abstract

Section: Discussionmentioning

confidence: 99%

Correlation between anxiety and decreased quality of life in patients with non‐esophageal eosinophilic gastrointestinal diseases

Tanaka,

Kanamori,

Sawada

et al. 2023

JGH Open

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, enrollment of EoE patients in a phase I clinical trial for barzolvolimab has begun, and our model suggests a beneficial role in blocking SCF. A number of studies have found that mast cells can be an indicator of disease severity, even when eosinophil numbers have decreased, suggesting that blocking SCF from binding to c-kit may provide beneficial reductions in mast cells, eosinophils, and ILC2s 23 , 24 , 68 , 69 . As all cell types activated by SCF have been shown to play a role in the development of fibrosis during disease, targeting this cytokine may be beneficial in halting EoE progression.…”

Section: Discussionmentioning

confidence: 99%

“…Stem cell factor (SCF), also known as kit ligand, has been previously described as an important factor in driving allergic disease. The receptor for SCF, c-kit, is expressed on the surface of many cells including eosinophils, mast cells, and type 2 innate lymphoid cells (ILC2s), all of which are cell populations that contribute to allergic diseases, including EoE 19 – 24 . Previous studies have found that SCF is upregulated in patients with allergic diseases such as asthm, and that an increased levels of SCF in serum correlated with severe disease 25 , 26 .…”

Section: Introductionmentioning

confidence: 99%

Stem cell factor inhibition reduces Th2 inflammation and cellular infiltration in a mouse model of eosinophilic esophagitis

Ptaschinski

Zhu²,

Fonseca³

et al. 2023

Mucosal Immunology

View full text Add to dashboard Cite

“…Endoscopic and histological findings do not differ substantially between aEE and symptomatic EoE 12 13 14 . Esophageal wall thickness and intraepithelial mast cells have been reported to be associated with the perception of esophageal symptoms 15 16 17 . In clinical practice, aEE and mEoE are likely to be followed up without active treatment; nonetheless, their natural course is not well-known 7 14 18 19 .…”

Section: Introductionmentioning

confidence: 99%

Long-term course of untreated asymptomatic esophageal eosinophilia and minimally symptomatic eosinophilic esophagitis

Abe,

Kikuchi,

Sasaki

et al. 2024

Endosc Int Open

View full text Add to dashboard Cite

Background/study aim: The long-term course of untreated asymptomatic esophageal eosinophilia (aEE) and minimally symptomatic eosinophilic esophagitis (mEoE) are not well understood. This study aimed to clarify this course. Patients and Methods: A total of 36 patients with EE who were endoscopically followed up for more than 5 years, and who underwent more than one endoscopy evaluation after the first diagnosis, were investigated. These patients were divided into two groups according to the presence or absence of the continuous treatment: no treatment group (NT group, n=22) and proton pump inhibitor/potassium competitive acid blocker group (Tx group, n=14). Symptoms and endoscopic and histological findings were retrospectively reviewed according to endoscopic phenotypes. Endoscopic assessment was performed using the EoE endoscopic reference score (EREFS). Results: The median follow-up period was 84.5 months in the Tx group and 92 months in the NT group. During the follow-up period, about half of the patients in the Tx-diffuse group persisted EREFS>3, while the remaining half had EREFS≤2. The total EREFS in the NT-diffuse group remained almost unchanged (median: 2–4) without apparent exacerbation. In contrast, EREFS in the NT-localized group exhibited an unchanged or gradually decreasing trend, with statistical significance from the first diagnosis to 72–83 months after. Conclusions: Untreated aEE and mEoE are not likely to worsen even without treatment at least for a median follow-up of 7 years. Instead, the localized type may spontaneously improve, implying a different pathogenesis in the presence of the diffuse type. Further studies should clarify the long-term prognosis.

show abstract

Esophageal mast cells may be associated with the perception of symptoms in patients with eosinophilic esophagitis

Cited by 9 publications

References 30 publications

Correlation between anxiety and decreased quality of life in patients with non‐esophageal eosinophilic gastrointestinal diseases

Correlation between anxiety and decreased quality of life in patients with non‐esophageal eosinophilic gastrointestinal diseases

Stem cell factor inhibition reduces Th2 inflammation and cellular infiltration in a mouse model of eosinophilic esophagitis

Long-term course of untreated asymptomatic esophageal eosinophilia and minimally symptomatic eosinophilic esophagitis

Contact Info

Product

Resources

About